Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds （3-10）, N-（3-nitro-2- hydroxylbenzylidene）-3-ferrocenylimine 0）, N-（3-bromo-2-hydroxylbenzylidene）-3-ferrocenylimine （4）, N-（3-bromo-5-chlorosalicylidene）- 3-ferrocenylimine （5）, N-（ferrocenylformidene）-3-ferrocenylimine （6）, N-（3-nitro-2-hydroxylbenzylidene）-4-ferrocenylimine （7）, N-（3-bromo-2-hydroxylbenzylidene）-4-ferrocenylimine （8）, N-（3-bromo-5-chlorosalicyl）-4-ferrocenylimine （9）, N-（ferrocenylformidene）- 4-ferrocenylimine （10） on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds （3-10） were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline （compound 1） and 4-ferrocenylaniline （compound 2）. Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.